Adjuvance Technologies Inc.

11:00 AM - 11:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Adjuvance Technologies is advancing synthetic saponin vaccine adjuvants for infectious disease, immuno-oncology and other applications. Our lead project is TQL1055, an optimized analogue of the saponin adjuvant QS-21, which is a critical component of the AS01 adjuvant used in the zoster vaccine commercialized by GSK. Among the improved attributes of 1055, are ample supply and improved tolerability, both of which are substantial issues for QS-21 and Shingrix.
Adjuvance has received $4M of NIH funding to date, and recently closed a $20M Series A round. This funding will enable us to get 1055 through a phase 1/2 clinical trial in infectious disease, and also allow us to explore other indications such as immuno-oncology and neurobiology.
Company Type:
Company HQ State:
Nebraska
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Lead Product in Development:
TQL1055
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1